BTIG lowered the firm’s price target on Akebia (AKBA) to $4 from $5 and keeps a Buy rating on the shares. The firm is citing a new US Renal Care protocol related to observed dosing contributed to a decrease in channel inventory of $4.5M-$5.0M, leading to a lower-than-expected Vafseo revenue recognized in Q4 of $5M-$6M, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics (AKBA) Q4 Earnings Cheat Sheet
- Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
- Akebia price target lowered to $4 from $6 at Piper Sandler
- Akebia Therapeutics Updates Executive Severance and Leadership Terms
- Akebia announces corporate updates, 2026 pipeline outlook